Vitamin E in Osteoporosis Management: An Evidence-Based Perspective

Abstract

Vitamin E is an antioxidant that has attracted considerable interest for the prevention of osteoporosis, particularly among postmenopausal women who are at high risk of bone loss. Evidence from animal models and cellular studies indicates that tocotrienols can reduce oxidative stress, modulate the RANKL/OPG (receptor activator of nuclear factor kappa B ligand/osteoprotegerin) pathway, inhibit NF-κB (nuclear factor kappa B) signaling, and stimulate osteoblast activity. These mechanisms collectively lead to a reduction in osteoclast formation and an increase in bone synthesis, thereby improving bone microarchitecture and reducing systemic bone resorption markers. In addition, clinical studies in humans have shown consistent findings, with mixed tocopherol supplementation significantly reducing bone resorption markers. Observational studies also suggest that individuals with higher vitamin E intake have a lower risk of osteoporosis, particularly among those with a prior history of fractures. However, evidence from randomized controlled trials in humans remains limited in terms of sample size, short study duration, and a lack of differentiation between vitamin E isoforms. Consequently, the efficacy of vitamin E in increasing bone mineral density cannot yet be clearly concluded. Therefore, pharmacists play an important role in providing accurate guidance on vitamin E use as a complementary option for bone health alongside standard medical treatment.